SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 19th, 2017 • Immune Pharmaceuticals Inc • Pharmaceutical preparations • New York
This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of April 10, 2017, is entered into by and between IMMUNE PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and EMA Financial, LLC, a Delaware limited liability company (the “Purchaser”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • April 19th, 2017 • Immune Pharmaceuticals Inc • Pharmaceutical preparations
This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and each Purchaser (the “Purchase Agreement”).
COMMON STOCK PURCHASE WARRANT IMMUNE PHARMACEUTICALS, INC.Common Stock Purchase Warrant • April 19th, 2017 • Immune Pharmaceuticals Inc • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, EMA Financial, LLC, a Delaware limited liability company (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after October 10, 2017 (as defined above) and on or prior to the close of business October 10, 2022 (the “Termination Date”) but not thereafter, to subscribe for and purchase from IMMUNE PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), up to 1,666,667 shares (the “Warrant Shares”) (whereby such number may be adjusted from time to time pursuant to the terms and conditions of this Warrant) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b), subject to adjustment herein. This Warrant is issued by the Company as of the date hereof in connection with the Purchase Agreement (as defined below).
